This notion has been supported by recent clinical data that report, not only the safe use of these treatments in patients, but also their efficacy to inhibit inflammatory ligands (IL-6, C-reactive protein), preserve the levels of cytokines that enhance anti-tumor activity by NK and cytotoxic T cells (IL-12, IFN-γ), decrease tumor infiltration with pro-inflammatory monocytes and abrogate the activity of immune suppressive CD4 T cells [157, 158]. The gene discussed is CD4; the disease is neoplasm.